14/11/2019 |
Final Share Issue to La Jolla Cove – Appendix 3B |
28/12/2012 |
Change in Director’s Interest – M Rogers |
14/12/2012 |
Change in Director’s Interest – M Halasz |
04/12/2012 |
Change in Director’s Interest – M Halasz |
04/12/2012 |
Change in Director’s Interest – M Rogers |
23/11/2012 |
AGM presentation |
23/11/2012 |
Result of Meeting |
20/11/2012 |
Investor Presentation |
09/11/2012 |
Change in Director’s Interest – M Rogers |
07/11/2012 |
Change in Director’s Interest – D King |
07/11/2012 |
Change in Director’s Interest – M Halasz |
29/10/2012 |
Amended Top 20 Option Holders |
29/10/2012 |
Dispatch of Options Entitlements Offer Holding Statements |
24/10/2012 |
$545K Options Rights Issue Completed |
24/10/2012 |
Annual Report to Shareholders |
24/10/2012 |
Notice of Annual General Meeting and Proxy Form |
22/10/2012 |
Appendix 4C – quarterly |
02/10/2012 |
$748K R&D Tax Credit Received |
02/10/2012 |
Change in Director’s Interest – M Halasz |
30/09/2012 |
Appendix 4E and Preliminary Final Report |
20/09/2012 |
Initial Director’s Interest Notice – M Rogers |
19/09/2012 |
Appointment of Director |
14/09/2012 |
Underwritten Non-Renounceable Pro-Rata Offer and Placement of Options |
13/09/2012 |
évolis® Hair Growth Products Exceed Distribution Targets |
04/09/2012 |
Exclusive Distributor Appointed for évolis® |
28/08/2012 |
Initial Director’s Interest – G Kaufman |
27/08/2012 |
Appointment and Resignation of Directors |
21/08/2012 |
Appendix 3B |
06/08/2012 |
Appointment of Joint Company Secretary |
30/07/2012 |
Cellmid News |
27/07/2012 |
Appendix 3B |
26/07/2012 |
Midkine Ischemia Patent Allowed in US |
23/07/2012 |
Appendix 4C |
12/07/2012 |
Change of Director’s Interest Notice – M Halasz |
25/06/2012 |
2nd Midkine Conference |
07/06/2012 |
Appendix 3B |
30/05/2012 |
évolis to be sold at Terry White |
28/05/2012 |
Results of Meeting |
25/05/2012 |
Change in substantial holding |
11/05/2012 |
Ceasing to be a substantial holder |
07/05/2012 |
Appendix 3B |
07/05/2012 |
Treg Antibody Patent Allowed in USA |
30/04/2012 |
Notice of Extraordinary General Meeting / Proxy Form |
26/04/2012 |
Appendix 4C |
24/04/2012 |
Cellmid Completes $1.5M Placement |
19/04/2012 |
Commercial website launched for évolis™ |
18/04/2012 |
USA Antibody Patent for Adhesion Allowed |
16/04/2012 |
Appendix 3B |
04/04/2012 |
Appendix 3B |
03/04/2012 |
Change of Director’s Interest Notice – R Beaumont |
29/03/2012 |
Appendix 3B |
29/03/2012 |
Media Launch of évolis™ Hair Products |
16/03/2012 |
Appendix 3B |
13/03/2012 |
Change of Director’s Interest Notice – M Halasz |
06/03/2012 |
Appendix 3B |
05/03/2012 |
Annual Report on Celera (Quest) License |
28/02/2012 |
Appendix 3B |
28/02/2012 |
Appendix 4D and Half Year Accounts |
20/02/2012 |
Appendix 3B |
20/02/2012 |
Notice of Change of Interest of Substantial Holder |
15/02/2012 |
TGA Registration and Launch of Cellmid’s évolis™ Products |
13/02/2012 |
La Jolla Funding Agreement Termination |
30/01/2012 |
Appendix 3B |
30/01/2012 |
Appendix 4C |